Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.21 USD
-0.05 (-1.17%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $4.20 -0.01 (-0.24%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth D Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Vanda Pharmaceuticals Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
VNDA 4.21 -0.05(-1.17%)
Will VNDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VNDA
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Other News for VNDA
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising ...
Q2 2025 Vanda Pharmaceuticals Inc Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Projects Cash Holdings of $280M-$320M by End of 2025
Vanda Pharmaceuticals (VNDA) Reports Lower Q2 Revenue than Expected
Vanda Pharmaceuticals reports Q2 EPS (46c) vs. (8c) last year